Anaptysbio (ANAB) Net Cash Flow (2016 - 2026)

Anaptysbio's Net Cash Flow history runs 11 years deep, the most recent figure standing at $10.3 million for Q1 2026.

• Quarterly Net Cash Flow rose 142.03% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $149.8 million (up 233.39% YoY) and the FY2025 annual result came in at $115.1 million, up 32.14% from the prior year.
• Net Cash Flow was $10.3 million for Q1 2026 at Anaptysbio, down from $128.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $128.4 million in Q4 2025 and bottomed at -$329.3 million in Q1 2022.
• A 5-year average of -$14.5 million and a median of $9.7 million in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 1077.43% — and 2024, when it surged 1443.96%.
• Anaptysbio's Net Cash Flow stood at $12.8 million in 2022, then declined by 24.22% to $9.7 million in 2023, then slumped by 808.39% to -$68.5 million in 2024, then surged by 287.39% to $128.4 million in 2025, then plunged by 92.0% to $10.3 million in 2026.
• Business Quant data shows ANAB's Net Cash Flow at $10.3 million in Q1 2026, $128.4 million in Q4 2025, and $65.5 million in Q3 2025.